<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/ct2/show/NCT04402047</url>
  </required_header>
  <id_info>
    <org_study_id>2020-015-KY</org_study_id>
    <nct_id>NCT04402047</nct_id>
  </id_info>
  <brief_title>Electroacupuncture vs Topical Diclofenac Sodium Gel for Patients With Hand Osteoarthritis</brief_title>
  <official_title>Electroacupuncture vs Topical Diclofenac Sodium Gel for Patients With Hand Osteoarthritis: Study Protocol for a Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Guang'anmen Hospital of China Academy of Chinese Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Guang'anmen Hospital of China Academy of Chinese Medical Sciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hand osteoarthritis (OA) is a prevalent joint disorder characterized by pain, stiffness, and&#xD;
      bony enlargements/swellings of multiple joints, in particular distal interphalangeal (DIP),&#xD;
      proximal interphalangeal (PIP) and first carpometacarpal (CMC) joints. Symptomatic hand OA is&#xD;
      estimated to affecting 15.9% of women and 8.2% of men in the general population with a&#xD;
      variable disease course, occurring more frequently in the elderly. Many factors including&#xD;
      age, gender, obesity, genetic predisposition, joint deformity, joint hypermobility, and&#xD;
      trauma are implicated in the development of hand OA. In addition to pain and stiffness,&#xD;
      patients with hand OA often suffer from the reduced grip and pinch strength, decreased range&#xD;
      of motion in involved and noninvolved joints, and difficulty performing dexterous tasks,&#xD;
      resulting in disability in activities of daily living and considerable frustration.&#xD;
&#xD;
      At present, no therapies can completely cure hand OA and few therapeutic options with proven&#xD;
      effectiveness for hand OA exist. Diclofenac sodium gel (DSG) is one of the commonly used&#xD;
      topical NSAIDs, which can provide local pain relief for patients with hand OA with reduced&#xD;
      systemic exposure, potentially reducing the risk of adverse events (AE). Acupuncture is&#xD;
      effective in a host of pain-related conditions, ranging from low back pain, neck pain,&#xD;
      shoulder pain, migraine to pain from knee OA. The research on the effects of acupuncture in&#xD;
      people with hand OA is very limited.&#xD;
&#xD;
      The purpose of this study is to investigate the clinical effectiveness of 4-week&#xD;
      electroacupuncture(EA) compared to topical DSG in the treatment of hand OA. Our primary&#xD;
      hypothesis was that EA would result in a greater pain relief improvement in hand OA compared&#xD;
      with topical DSG.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">September 1, 2020</start_date>
  <completion_date type="Anticipated">February 28, 2023</completion_date>
  <primary_completion_date type="Anticipated">August 31, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
    <masking_description>Efficacy evaluators and data analysts will be blinded to the group assignments.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Change in average overall finger joints pain intensity in the dominant hand over the past 48h from baseline to week 4</measure>
    <time_frame>at baseline and week 4</time_frame>
    <description>Pain intensity will be measured using a 0-100 VAS, with 0 indicating no pain and 100 indicating maximal pain.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in average overall finger joints pain intensity in the dominant hand over the past 48h from baseline to weeks 8, 16</measure>
    <time_frame>at baseline，week 8 and week 16</time_frame>
    <description>Pain intensity will be measured using a 0-100 VAS, with 0 indicating no pain and 100 indicating maximal pain.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The proportion of participants achieving at least a 15-point reduction in average overall finger joints pain intensity in the dominant hand from baseline to weeks 4, 8 and 16</measure>
    <time_frame>at week 4, week 8 and week 16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Australian Canadian Osteoarthritis Hand Index (AUSCAN) total score, and pain, stiffness and physical function subscales from baseline to weeks 4, 8 and 16</measure>
    <time_frame>at baseline，week 4, week 8 and week 16</time_frame>
    <description>The AUSCAN index contains a 15-item scale referring to hand pain (5 items), stiffness (1 item), and function (9 items) during the preceding 48 hours, which is valid, reliable and responsive in patients with hand OA. All items are scaled on a 0-100 VAS (0=none to 100= very severe), with higher scores indicating more severe symptoms/function.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Functional Index for HOA (FIHOA) from baseline to weeks 4, 8 and 16</measure>
    <time_frame>at baseline，week 4, week 8 and week 16</time_frame>
    <description>The FIHOA is a patient-reported hand function questionnaire, comprising 10 items with a four-point Likert scale, in which 0 represents &quot;possible without difficulty&quot;, 1 indicates &quot;possible with slight difficulty&quot;, 2 represents &quot;possible with important difficulty&quot; and 3 indicates &quot;impossible&quot;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the number of self-reported painful joints and painful joints at digital pressure from baseline to weeks 4, 8 and 16</measure>
    <time_frame>at baseline，week 4, week 8 and week 16</time_frame>
    <description>All finger joints will be reported spontaneously for the presence of pain by the participants, and examined by a trained research nurse for the presence of pain at digital pressure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the number of swollen joints from baseline to weeks 4, 8 and 16:</measure>
    <time_frame>at baseline，week 4, week 8 and week 16</time_frame>
    <description>All soft swollen finger joints count (0-30) will be assessed by a trained research nurse at each study visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in hand grip strength and pinch strength of the fingers from baseline to weeks 4, 8 and 16:</measure>
    <time_frame>at baseline，week 4, week 8 and week 16</time_frame>
    <description>Hand grip strength and pinch strength of the fingers of the dominant hand will be tested using a hand dynamometer and a Jamar digital pinch gauge respectively.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in patient global assessment of improvement from baseline to weeks 4, 8 and 16</measure>
    <time_frame>at baseline，week 4, week 8 and week 16</time_frame>
    <description>The patients will be asked to respond to the question 'Considering all the ways your hand OA affects you, how have you been during the last 48 h?' on a self-administered 0-100 VAS (0, worst possible, to 100, best possible, in 10-point increments)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The proportion of responder according to the Outcome Measures in Rheumatological Clinical Trials (OMERACT) and Osteoarthritis Research Society International (OARSI) responder criteria at weeks 4，8 and 16</measure>
    <time_frame>at week 4, week 8 and week 16</time_frame>
    <description>The OMERACT-OARSI response is defined as an improvement in either pain (0-100 overall finger joints pain) or function (0-36 AUSCAN physical function) with ≥50% (relative) and ≥20/100 (absolute); or if the improvement is ≥20% (relative) and ≥10/100 (absolute) in ≥2 of the following: pain, functioning and patient global assessment of improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in quality of life assessed by the World Health Organization Quality of Life abbreviated version (WHOQOL-BREF) from baseline to weeks 4, 8 and 16</measure>
    <time_frame>at baseline，week 4, week 8 and week 16</time_frame>
    <description>The WHOQOL-BREF is a 26-item self-report questionnaire rated on a 5-point Likert-type scale with four domains of QOL: physical (seven items), psychological (six items), social (three items), and environment (eight items), plus 2 items representing the general QOL. The four domain scores are scaled in a positive direction with higher scores indicating a higher quality of life.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Self-reported consumption of acetaminophen for hand OA during weeks 1-4 and weeks 5-12</measure>
    <time_frame>at weeks 1-4 and weeks 5-12</time_frame>
    <description>The proportion of participants using acetaminophen and the average dosage of acetaminophen used weekly will be calculated and assessed.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Participants' expectations for acupuncture at baseline</measure>
    <time_frame>at baseline</time_frame>
    <description>At baseline, participants in the EA group will be asked to answer the following question: &quot;What do you expect from EA treatment to improve your hand OA?&quot;</description>
  </other_outcome>
  <other_outcome>
    <measure>Incidence of adverse events</measure>
    <time_frame>weeks 1-16</time_frame>
    <description>Any adverse events (AEs) during the whole study, whether reported spontaneously by the participants, or observed by the researcher, will be recorded and categorized as acupuncture-related AEs(e.g., fainting, broken needle, localized hematoma, dizziness, or), the side effect of TDG (e.g., skin irritation/itching, reddening, scaly skin), and non-treatment-related AEs. All AEs will be recorded in detail in the case report form.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">108</enrollment>
  <condition>Hand Osteoarthritis</condition>
  <arm_group>
    <arm_group_label>Electroacupuncture group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Topical DSG group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Electroacupuncture</intervention_name>
    <description>We will apply Ashi points, Ex-UE9, SI3, and TE5. Sterile needles (0.3mm× 40mm) and SDZ-V EA apparatus will be utilized. Acupuncturists will insert needles perpendicularly into Ashi points for approximately 2-3mm until they pierce into the bone surface; acupuncturists will insert needles horizontally into Baxie points towards the wrist with a depth of 5-10mm; and acupuncturists will insert needles perpendicularly into SI3 and TE5 for approximately 5-10mm. All needles except Ashi points will be manually manipulated to achieve De qi. The needles at Baxie 1 and Baxie 4 will be connected using alligator clips from the EA apparatus. The electrical stimulation will last for 30 minutes with a continuous wave of 10 Hz and a fixed current intensity of 0.5 to 2 mA. All the needles will be retained for 30 minutes. Participants will undergo EA treatment three times per week for a total of 12 sessions in four consecutive weeks. If bilateral hands were affected, both sides will be treated.</description>
    <arm_group_label>Electroacupuncture group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Topical diclofenac sodium gel</intervention_name>
    <description>The gel will be gently rubbed over the affected joints without excessive joint movement four times per day for 4 weeks and will be asked not to wash hands for one hour after application. Each hand treatment will be used in identical dispensing doses of gel (4 cm strip, approximately 2g, which was judged sufficient for approximately half the surface of each hand (200 cm2)). Dosing times should be distributed evenly over waking hours.If bilateral hands were affected, both sides will be treated.</description>
    <arm_group_label>Topical DSG group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. History of hand OA for at least 3 months before enrolment and use of a NASID for ≥ 1&#xD;
             episode of pain;&#xD;
&#xD;
          2. Reported an average possible overall finger joints pain intensity in the dominant hand&#xD;
             over the past 48 hours of at least 40mm according to a 100-mm visual analog scale&#xD;
             (VAS) after 1-week wash-out period of previous OA medications(Patients applying NSAIDs&#xD;
             at the screening had to have an increase in pain in the dominant hand of ≥ 20 mm&#xD;
             during washout);&#xD;
&#xD;
          3. Posterior-anterior radiographs had to show Kellgren-Lawrence grade 1, 2, or 3 changes&#xD;
             in symptomatic joints;&#xD;
&#xD;
          4. Rheumatoid factor and anticyclonic citrullinated peptide were negative in all eligible&#xD;
             participants to exclude inflammatory arthritis;&#xD;
&#xD;
          5. Ability to comply with the study protocol, understand the medical information forms as&#xD;
             well as having signed informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. History or current evidence of secondary OA(due to causes other than a solely&#xD;
             degenerative joint disease) or symptomatic OA at additional locations besides the&#xD;
             hand(s) requiring treatment, or any painful syndrome of the upper limb which may&#xD;
             interfere with evaluation of hand pain;&#xD;
&#xD;
          2. History of inflammatory arthritis(e.g., rheumatoid arthritis (RA), psoriatic&#xD;
             arthritis), hemochromatosis, metabolic, or neuropathic arthropathies;&#xD;
&#xD;
          3. History of trauma, dislocation or operation to the hand or arm in the previous 3&#xD;
             months;&#xD;
&#xD;
          4. Hand pain and stiffness due to tissue scarring or tendinitis;&#xD;
&#xD;
          5. Skin damage or serious skin disorders in the hands;&#xD;
&#xD;
          6. Intake of antidepressants, anticonvulsants, vascular or narcotics during the 10 days&#xD;
             prior to beginning the study;&#xD;
&#xD;
          7. Oral, intramuscular, intra-articular or intravenous corticosteroids, or hyaluronic&#xD;
             acid injection within 3 months preceding enrollment;&#xD;
&#xD;
          8. Serious uncontrolled medical conditions such as cancer, uncontrolled cardiovascular&#xD;
             disorder, severe hepatic/renal insufficiency or coagulation disorder;&#xD;
&#xD;
          9. Known allergy, contraindication or intolerance to diclofenac, acetaminophen, or gel&#xD;
             components;&#xD;
&#xD;
         10. Known phobic to acupuncture or received acupuncture treatment within 4 weeks prior to&#xD;
             enrollment.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zhishun Liu, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Acupuncture, Guang'anmen Hospital, China Academy of Chinese Medical Sciences</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>weiming wang, MD, PhD</last_name>
    <phone>010-88001241</phone>
    <email>wangweiming1a1@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Zhishun Liu, MD, PhD</last_name>
    <phone>010-88002331</phone>
    <email>zhishunjournal@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Acupuncture and Moxibustion, China Academy of Chinese Medical Sciences Guang'anmen Hospital</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>May 20, 2020</study_first_submitted>
  <study_first_submitted_qc>May 20, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 26, 2020</study_first_posted>
  <last_update_submitted>October 6, 2020</last_update_submitted>
  <last_update_submitted_qc>October 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 8, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Guang'anmen Hospital of China Academy of Chinese Medical Sciences</investigator_affiliation>
    <investigator_full_name>Liu Zhishun</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Hand osteoarthritis; Electroacupuncture; Diclofenac sodium gel</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diclofenac</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Individual participant data are available on reasonable request. You can send e-mail to us if you have any question</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_time_frame>It depends</ipd_time_frame>
    <ipd_access_criteria>It depends</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>


download date: ClinicalTrials.gov processed this data on September 20, 2023
link text: Link to the current ClinicalTrials.gov record.
url: https://clinicaltrials.gov/ct2/show/NCT04402047
org study id: 2020-015-KY
nct id: NCT04402047
lead sponsor: 
has dmc: No
is fda regulated drug: No
is fda regulated device: No
Hand osteoarthritis (OA) is a prevalent joint disorder characterized by pain, stiffness, and
      bony enlargements/swellings of multiple joints, in particular distal interphalangeal (DIP),
      proximal interphalangeal (PIP) and first carpometacarpal (CMC) joints. Symptomatic hand OA is
      estimated to affecting 15.9% of women and 8.2% of men in the general population with a
      variable disease course, occurring more frequently in the elderly. Many factors including
      age, gender, obesity, genetic predisposition, joint deformity, joint hypermobility, and
      trauma are implicated in the development of hand OA. In addition to pain and stiffness,
      patients with hand OA often suffer from the reduced grip and pinch strength, decreased range
      of motion in involved and noninvolved joints, and difficulty performing dexterous tasks,
      resulting in disability in activities of daily living and considerable frustration.

      At present, no therapies can completely cure hand OA and few therapeutic options with proven
      effectiveness for hand OA exist. Diclofenac sodium gel (DSG) is one of the commonly used
      topical NSAIDs, which can provide local pain relief for patients with hand OA with reduced
      systemic exposure, potentially reducing the risk of adverse events (AE). Acupuncture is
      effective in a host of pain-related conditions, ranging from low back pain, neck pain,
      shoulder pain, migraine to pain from knee OA. The research on the effects of acupuncture in
      people with hand OA is very limited.

      The purpose of this study is to investigate the clinical effectiveness of 4-week
      electroacupuncture(EA) compared to topical DSG in the treatment of hand OA. Our primary
      hypothesis was that EA would result in a greater pain relief improvement in hand OA compared
      with topical DSG.
allocation: Randomized
intervention model: Parallel Assignment
primary purpose: Treatment
masking: Single (Outcomes Assessor)
masking description: Efficacy evaluators and data analysts will be blinded to the group assignments.
measure: Change in average overall finger joints pain intensity in the dominant hand over the past 48h from baseline to week 4
time frame: at baseline and week 4
description: Pain intensity will be measured using a 0-100 VAS, with 0 indicating no pain and 100 indicating maximal pain.
measure: Change in average overall finger joints pain intensity in the dominant hand over the past 48h from baseline to weeks 8, 16
time frame: at baseline，week 8 and week 16
description: Pain intensity will be measured using a 0-100 VAS, with 0 indicating no pain and 100 indicating maximal pain.
measure: The proportion of participants achieving at least a 15-point reduction in average overall finger joints pain intensity in the dominant hand from baseline to weeks 4, 8 and 16
time frame: at week 4, week 8 and week 16
measure: Change in Australian Canadian Osteoarthritis Hand Index (AUSCAN) total score, and pain, stiffness and physical function subscales from baseline to weeks 4, 8 and 16
time frame: at baseline，week 4, week 8 and week 16
description: The AUSCAN index contains a 15-item scale referring to hand pain (5 items), stiffness (1 item), and function (9 items) during the preceding 48 hours, which is valid, reliable and responsive in patients with hand OA. All items are scaled on a 0-100 VAS (0=none to 100= very severe), with higher scores indicating more severe symptoms/function.
measure: Change in Functional Index for HOA (FIHOA) from baseline to weeks 4, 8 and 16
time frame: at baseline，week 4, week 8 and week 16
description: The FIHOA is a patient-reported hand function questionnaire, comprising 10 items with a four-point Likert scale, in which 0 represents "possible without difficulty", 1 indicates "possible with slight difficulty", 2 represents "possible with important difficulty" and 3 indicates "impossible"
measure: Change in the number of self-reported painful joints and painful joints at digital pressure from baseline to weeks 4, 8 and 16
time frame: at baseline，week 4, week 8 and week 16
description: All finger joints will be reported spontaneously for the presence of pain by the participants, and examined by a trained research nurse for the presence of pain at digital pressure.
measure: Change in the number of swollen joints from baseline to weeks 4, 8 and 16:
time frame: at baseline，week 4, week 8 and week 16
description: All soft swollen finger joints count (0-30) will be assessed by a trained research nurse at each study visit.
measure: Change in hand grip strength and pinch strength of the fingers from baseline to weeks 4, 8 and 16:
time frame: at baseline，week 4, week 8 and week 16
description: Hand grip strength and pinch strength of the fingers of the dominant hand will be tested using a hand dynamometer and a Jamar digital pinch gauge respectively.
measure: Change in patient global assessment of improvement from baseline to weeks 4, 8 and 16
time frame: at baseline，week 4, week 8 and week 16
description: The patients will be asked to respond to the question 'Considering all the ways your hand OA affects you, how have you been during the last 48 h?' on a self-administered 0-100 VAS (0, worst possible, to 100, best possible, in 10-point increments)
measure: The proportion of responder according to the Outcome Measures in Rheumatological Clinical Trials (OMERACT) and Osteoarthritis Research Society International (OARSI) responder criteria at weeks 4，8 and 16
time frame: at week 4, week 8 and week 16
description: The OMERACT-OARSI response is defined as an improvement in either pain (0-100 overall finger joints pain) or function (0-36 AUSCAN physical function) with ≥50% (relative) and ≥20/100 (absolute); or if the improvement is ≥20% (relative) and ≥10/100 (absolute) in ≥2 of the following: pain, functioning and patient global assessment of improvement.
measure: Change in quality of life assessed by the World Health Organization Quality of Life abbreviated version (WHOQOL-BREF) from baseline to weeks 4, 8 and 16
time frame: at baseline，week 4, week 8 and week 16
description: The WHOQOL-BREF is a 26-item self-report questionnaire rated on a 5-point Likert-type scale with four domains of QOL: physical (seven items), psychological (six items), social (three items), and environment (eight items), plus 2 items representing the general QOL. The four domain scores are scaled in a positive direction with higher scores indicating a higher quality of life.
measure: Self-reported consumption of acetaminophen for hand OA during weeks 1-4 and weeks 5-12
time frame: at weeks 1-4 and weeks 5-12
description: The proportion of participants using acetaminophen and the average dosage of acetaminophen used weekly will be calculated and assessed.
measure: Participants' expectations for acupuncture at baseline
time frame: at baseline
description: At baseline, participants in the EA group will be asked to answer the following question: "What do you expect from EA treatment to improve your hand OA?"
measure: Incidence of adverse events
time frame: weeks 1-16
description: Any adverse events (AEs) during the whole study, whether reported spontaneously by the participants, or observed by the researcher, will be recorded and categorized as acupuncture-related AEs(e.g., fainting, broken needle, localized hematoma, dizziness, or), the side effect of TDG (e.g., skin irritation/itching, reddening, scaly skin), and non-treatment-related AEs. All AEs will be recorded in detail in the case report form.
arm group label: Electroacupuncture group
arm group type: Experimental
arm group label: Topical DSG group
arm group type: Active Comparator
intervention type: Other
intervention name: Electroacupuncture
description: We will apply Ashi points, Ex-UE9, SI3, and TE5. Sterile needles (0.3mm× 40mm) and SDZ-V EA apparatus will be utilized. Acupuncturists will insert needles perpendicularly into Ashi points for approximately 2-3mm until they pierce into the bone surface; acupuncturists will insert needles horizontally into Baxie points towards the wrist with a depth of 5-10mm; and acupuncturists will insert needles perpendicularly into SI3 and TE5 for approximately 5-10mm. All needles except Ashi points will be manually manipulated to achieve De qi. The needles at Baxie 1 and Baxie 4 will be connected using alligator clips from the EA apparatus. The electrical stimulation will last for 30 minutes with a continuous wave of 10 Hz and a fixed current intensity of 0.5 to 2 mA. All the needles will be retained for 30 minutes. Participants will undergo EA treatment three times per week for a total of 12 sessions in four consecutive weeks. If bilateral hands were affected, both sides will be treated.
arm group label: Electroacupuncture group
intervention type: Drug
intervention name: Topical diclofenac sodium gel
description: The gel will be gently rubbed over the affected joints without excessive joint movement four times per day for 4 weeks and will be asked not to wash hands for one hour after application. Each hand treatment will be used in identical dispensing doses of gel (4 cm strip, approximately 2g, which was judged sufficient for approximately half the surface of each hand (200 cm2)). Dosing times should be distributed evenly over waking hours.If bilateral hands were affected, both sides will be treated.
arm group label: Topical DSG group
criteria: 
gender: All
minimum age: 18 Years
maximum age: 80 Years
healthy volunteers: No
last name: Zhishun Liu, MD, PhD
role: Principal Investigator
affiliation: Department of Acupuncture, Guang'anmen Hospital, China Academy of Chinese Medical Sciences
last name: weiming wang, MD, PhD
phone: 010-88001241
email: wangweiming1a1@163.com
last name: Zhishun Liu, MD, PhD
phone: 010-88002331
email: zhishunjournal@163.com
facility: 
status: Recruiting
country: China
responsible party type: Principal Investigator
investigator affiliation: Guang'anmen Hospital of China Academy of Chinese Medical Sciences
investigator full name: Liu Zhishun
investigator title: Principal Investigator
mesh term: Osteoarthritis
mesh term: Diclofenac
sharing ipd: Yes
ipd description: Individual participant data are available on reasonable request. You can send e-mail to us if you have any question
ipd info type: Study Protocol
ipd info type: Statistical Analysis Plan (SAP)
ipd time frame: It depends
ipd access criteria: It depends